Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Urological ScienceOpen Access

Validation of neutrophil-to-lymphocyte ratio for prognosis and treatment selection in muscle-invasive bladder cancer: A single-institutional longitudinal study

View Full Paper
Ask AI
Bookmark
Share

Authors

STSheng‐Feng TsaiTCTing‐Yi ChiangWTWen‐Hsin Tseng

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows neutrophil-to-lymphocyte ratio predicts outcomes in muscle-invasive bladder cancer, guiding treatment options.

Key Points

  • High neutrophil-to-lymphocyte ratio is linked to shorter time to recurrence and increased mortality rates.
  • Patients with a low neutrophil-to-lymphocyte ratio undergoing radical cystectomy have better disease-free survival.
  • Multivariate analysis indicates advanced tumor staging as a significant predictor of recurrence and death.
  • Elevated neutrophil-to-lymphocyte ratio can help stratify muscle-invasive bladder cancer patients for treatment decisions.

Cite This Study

Tsai et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790064https://doi.org/10.1097/us9.0000000000000095
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Significance of Pre-Treatment Serum Markers in Muscle-Invasive Bladder Cancer Under Tri-Modality Therapy2025
  2. 2Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study2025
  3. 3Neutrophil to Lymphocyte Ratio a Prognostic Tool in Endometrial Cancer Among Classical Prognostic Factors2025
  4. 4Prognostic value of neutrophil to lymphocyte ratio in patients with esophagus cancer receiving neoadjuvant therapy: a systematic review and meta-analysis2025 · 3 citations
  5. 5Prognostic value of combined tumor regression grade and TNM stage in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy2025